Clinical research has now restarted, and we're funding further studies!
Understanding Parkinson's
In Parkinson’s, a protein called alpha-synuclein which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. Cure Parkinson's is investigating how this and other key biochemical pathways and events contribute to the progression of Parkinson's; and thanks to our supporters, we’re funding research into the most promising therapeutic areas.
Find out moreAnle138b to target the toxic protein in Parkinson’s
Alpha-synuclein is considered “public enemy number one” in Parkinson’s research. We have known since the 1990s that the aggregation of this protein inside of neurons is one of the characteristic features of the Parkinson’s brain. There are currently many clinical trials underway targeting alpha-synuclein and trying to remove the aggregates.
Read more here
Take part in research
The ADepT-PD Trial
This trial is recruiting people to take part in 30 centres across the UK. We fund and support clinical trials which seek to slow, stop or reverse Parkinson’s. Find out more...
Donate
Please consider donating today to help us progress our research with urgency towards a cure
